AST 0 3 0 3 B-clinical_variable
( 4 5 4 5 I-clinical_variable
SGOT)/ALT 5 14 5 14 I-clinical_variable
( 15 16 15 16 I-clinical_variable
SGPT 16 20 16 20 I-clinical_variable
) 20 21 20 21 I-clinical_variable
≤2.5 22 26 22 26 O
× 27 28 27 28 I-upper_bound
upper 29 34 29 34 I-upper_bound
limit 35 40 35 40 I-upper_bound
of 41 43 41 43 I-upper_bound
normal 44 50 44 50 I-upper_bound
creatinine 51 61 51 61 B-clinical_variable
OR 62 64 62 64 O
creatinine 65 75 65 75 B-clinical_variable
clearance 76 85 76 85 I-clinical_variable
≥60 86 89 86 89 O
mL 90 92 90 92 I-lower_bound
/ 92 93 92 93 I-lower_bound
min/1.73 93 101 93 101 I-lower_bound
m2 102 104 102 104 I-lower_bound
for 105 108 105 108 O
patients 109 117 109 117 O
with 118 122 118 122 O
creatinine 123 133 123 133 O
levels 134 140 134 140 O
above 141 146 141 146 O
normal 147 153 147 153 O

Active 0 6 154 160 B-chronic_disease
infection 7 16 161 170 I-chronic_disease
requiring 17 26 171 180 O
systemic 27 35 181 189 B-treatment
therapy 36 43 190 197 I-treatment

All 0 3 198 201 O
adverse 4 11 202 209 O
events 12 18 210 216 O
Grade 19 24 217 222 O
> 25 26 223 224 O
1 27 28 225 226 B-lower_bound
related 29 36 227 234 O
to 37 39 235 237 O
prior 40 45 238 243 B-treatment
therapies 46 55 244 253 I-treatment
( 56 57 254 255 O
chemotherapy 57 69 255 267 B-treatment
, 69 70 267 268 O
radiotherapy 71 83 269 281 B-treatment
, 83 84 281 282 O
and/or 85 91 283 289 O
surgery 92 99 290 297 B-treatment
) 99 100 297 298 O
must 101 105 299 303 O
be 106 108 304 306 O
resolved 109 117 307 315 O
, 117 118 315 316 O
except 119 125 317 323 O
for 126 129 324 327 O
alopecia 130 138 328 336 B-chronic_disease

Any 0 3 337 340 O
surgery 4 11 341 348 B-treatment
( 12 13 349 350 O
not 13 16 350 353 O
including 17 26 354 363 O
minor 27 32 364 369 B-treatment
diagnostic 33 43 370 380 I-treatment
procedures 44 54 381 391 I-treatment
such 55 59 392 396 O
as 60 62 397 399 O
lymph 63 68 400 405 B-treatment
node 69 73 406 410 I-treatment
biopsy 74 80 411 417 I-treatment
) 80 81 417 418 O
within 82 88 419 425 O
2 89 90 426 427 B-upper_bound
weeks 91 96 428 433 I-upper_bound
of 97 99 434 436 O
baseline 100 108 437 445 O
disease 109 116 446 453 O
assessments 117 128 454 465 O
; 128 129 465 466 O
or 130 132 467 469 O
not 133 136 470 473 O
fully 137 142 474 479 O
recovered 143 152 480 489 O
from 153 157 490 494 O
any 158 161 495 498 O
side 162 166 499 503 O
effects 167 174 504 511 O
of 175 177 512 514 O
previous 178 186 515 523 O
procedures 187 197 524 534 O

CT 0 2 535 537 B-treatment
or 3 5 538 540 O
MRI 6 9 541 544 B-treatment
within 10 16 545 551 O
14 17 19 552 554 B-upper_bound
days 20 24 555 559 I-upper_bound
prior 25 30 560 565 I-upper_bound
to 31 33 566 568 O
start 34 39 569 574 O
of 40 42 575 577 O
study 43 48 578 583 B-treatment
drug 49 53 584 588 I-treatment

Concomitant 0 11 589 600 O
use 12 15 601 604 O
of 16 18 605 607 O
CYP3A4/5 19 27 608 616 B-treatment
inhibitors 28 38 617 627 I-treatment
during 39 45 628 634 O
the 46 49 635 638 O
treatment 50 59 639 648 B-treatment
phase 60 65 649 654 O
of 66 68 655 657 O
the 69 72 658 661 O
study 73 78 662 667 O
and 79 82 668 671 O
within 83 89 672 678 O
72 90 92 679 681 B-upper_bound
hours 93 98 682 687 I-upper_bound
prior 99 104 688 693 I-upper_bound
to 105 107 694 696 O
starting 108 116 697 705 O
study 117 122 706 711 B-treatment
drug 123 127 712 716 I-treatment
administration 128 142 717 731 O

Concomitant 0 11 732 743 O
use 12 15 744 747 O
of 16 18 748 750 O
potent 19 25 751 757 O
CYP3A4/5 26 34 758 766 B-treatment
inducers 35 43 767 775 I-treatment
, 43 44 775 776 O
which 45 50 777 782 O
include 51 58 783 790 O
enzyme 59 65 791 797 B-treatment
inducing 66 74 798 806 I-treatment
antiepileptic 75 88 807 820 I-treatment
drugs 89 94 821 826 I-treatment
( 95 96 827 828 I-treatment
EIAEDs 96 102 828 834 I-treatment
) 102 103 834 835 I-treatment
( 104 105 836 837 O
see 105 108 837 840 O
Appendix 109 117 841 849 O
B 118 119 850 851 O
) 119 120 851 852 O
, 120 121 852 853 O
during 122 128 854 860 O
the 129 132 861 864 O
treatment 133 142 865 874 B-treatment
phase 143 148 875 880 O
of 149 151 881 883 O
the 152 155 884 887 O
study 156 161 888 893 O
and 162 165 894 897 O
within 166 172 898 904 O
2 173 174 905 906 B-upper_bound
weeks 175 180 907 912 I-upper_bound
prior 181 186 913 918 I-upper_bound
to 187 189 919 921 O
starting 190 198 922 930 O
treatment 199 208 931 940 O

Corticosteroid 0 14 941 955 B-treatment
dose 15 19 956 960 O
must 20 24 961 965 O
be 25 27 966 968 O
stable 28 34 969 975 O
or 35 37 976 978 O
decreasing 38 48 979 989 O
for 49 52 990 993 O
at 53 55 994 996 O
least 56 61 997 1002 O
5 62 63 1003 1004 B-lower_bound
days 64 68 1005 1009 I-lower_bound
prior 69 74 1010 1015 I-lower_bound
to 75 77 1016 1018 O
the 78 81 1019 1022 O
scan 82 86 1023 1027 O
. 86 87 1027 1028 O
For 88 91 1029 1032 O
Arm 92 95 1033 1036 O
B 96 97 1037 1038 O
: 97 98 1038 1039 O
Corticosteroid 99 113 1040 1054 O
dose 114 118 1055 1059 O
must 119 123 1060 1064 O
be 124 126 1065 1067 O
stable 127 133 1068 1074 O
or 134 136 1075 1077 O
decreasing 137 147 1078 1088 O
for 148 151 1089 1092 O
at 152 154 1093 1095 O
least 155 160 1096 1101 O
2 161 162 1102 1103 B-lower_bound
weeks 163 168 1104 1109 I-lower_bound
prior 169 174 1110 1115 I-lower_bound
to 175 177 1116 1118 O
study 178 183 1119 1124 O
entry 184 189 1125 1130 O

Current 0 7 1131 1138 O
or 8 10 1139 1141 O
planned 11 18 1142 1149 O
participation 19 32 1150 1163 O
in 33 35 1164 1166 O
a 36 37 1167 1168 O
study 38 43 1169 1174 O
of 44 46 1175 1177 O
an 47 49 1178 1180 O
investigational 50 65 1181 1196 B-treatment
agent 66 71 1197 1202 I-treatment
or 72 74 1203 1205 O
using 75 80 1206 1211 O
an 81 83 1212 1214 O
investigational 84 99 1215 1230 B-treatment
device 100 106 1231 1237 I-treatment

Female 0 6 1238 1244 B-gender

For 0 3 1245 1248 O
Arm 4 7 1249 1252 O
A 8 9 1253 1254 O
or 10 12 1255 1257 O
D 13 14 1258 1259 O
: 14 15 1259 1260 O
Any 16 19 1261 1264 O
number 20 26 1265 1271 O
of 27 29 1272 1274 O
recurrences 30 41 1275 1286 O
are 42 45 1287 1290 O
allowable 46 55 1291 1300 O
. 55 56 1300 1301 O
For 57 60 1302 1305 O
Arm 61 64 1306 1309 O
B 65 66 1310 1311 O
: 66 67 1311 1312 O
First 68 73 1313 1318 O
recurrence 74 84 1319 1329 O
( 85 86 1330 1331 O
only 86 90 1331 1335 O
) 90 91 1335 1336 O
WHO 92 95 1337 1340 O
Grade 96 101 1341 1346 O
glioma 102 108 1347 1353 B-cancer
. 108 109 1353 1354 O
First 110 115 1355 1360 O
recurrence 116 126 1361 1371 O
is 127 129 1372 1374 O
defined 130 137 1375 1382 O
as 138 140 1383 1385 O
progression 141 152 1386 1397 O
following 153 162 1398 1407 O
initial 163 170 1408 1415 O
therapy 171 178 1416 1423 O
( 179 180 1424 1425 O
i.e. 180 184 1425 1429 O
, 184 185 1429 1430 O
radiation 186 195 1431 1440 B-treatment
± 196 197 1441 1442 O
chemotherapy 198 210 1443 1455 B-treatment
) 210 211 1455 1456 O
. 211 212 1456 1457 O
For 213 216 1458 1461 O
participants 217 229 1462 1474 O
who 230 233 1475 1478 O
had 234 237 1479 1482 O
prior 238 243 1483 1488 B-treatment
therapy 244 251 1489 1496 I-treatment
with 252 256 1497 1501 I-treatment
radiation 257 266 1502 1511 I-treatment
or 267 269 1512 1514 O
chemotherapy 270 282 1515 1527 O
for 283 286 1528 1531 O
a 287 288 1532 1533 O
low 289 292 1534 1537 O
- 292 293 1537 1538 O
grade 293 298 1538 1543 O
glioma 299 305 1544 1550 O
, 305 306 1550 1551 O
the 307 310 1552 1555 O
surgical 311 319 1556 1564 B-treatment
diagnosis 320 329 1565 1574 I-treatment
of 330 332 1575 1577 O
a 333 334 1578 1579 O
high 335 339 1580 1584 B-cancer
- 339 340 1584 1585 I-cancer
grade 340 345 1585 1590 I-cancer
glioma 346 352 1591 1597 I-cancer
will 353 357 1598 1602 O
be 358 360 1603 1605 O
considered 361 371 1606 1616 O
the 372 375 1617 1620 O
first 376 381 1621 1626 O
recurrence 382 392 1627 1637 O
. 392 393 1637 1638 O
For 394 397 1639 1642 O
patients 398 406 1643 1651 O
who 407 410 1652 1655 O
did 411 414 1656 1659 O
not 415 418 1660 1663 O
get 419 422 1664 1667 O
additional 423 433 1668 1678 O
treatment 434 443 1679 1688 B-treatment
following 444 453 1689 1698 O
surgery 454 461 1699 1706 B-treatment
and 462 465 1707 1710 O
diagnosis 466 475 1711 1720 O
of 476 478 1721 1723 O
low 479 482 1724 1727 O
- 482 483 1727 1728 O
grade 483 488 1728 1733 O
glioma 489 495 1734 1740 O
, 495 496 1740 1741 O
surgical 497 505 1742 1750 O
diagnosis 506 515 1751 1760 O
of 516 518 1761 1763 O
high 519 523 1764 1768 B-cancer
grade 524 529 1769 1774 I-cancer
glioma 530 536 1775 1781 I-cancer
will 537 541 1782 1786 O
not 542 545 1787 1790 O
be 546 548 1791 1793 O
considered 549 559 1794 1804 O
the 560 563 1805 1808 O
first 564 569 1809 1814 O
recurrence 570 580 1815 1825 O
. 580 581 1825 1826 O
Instead 582 589 1827 1834 O
, 589 590 1834 1835 O
progression 591 602 1836 1847 O
after 603 608 1848 1853 B-treatment
treatment 609 618 1854 1863 I-treatment
will 619 623 1864 1868 O
be 624 626 1869 1871 O
considered 627 637 1872 1882 O
first 638 643 1883 1888 O
recurrence 644 654 1889 1899 O
. 654 655 1899 1900 O
For 656 659 1901 1904 O
Arm 660 663 1905 1908 O
C 664 665 1909 1910 O
: 665 666 1910 1911 O
Patients 667 675 1912 1920 O
must 676 680 1921 1925 O
have 681 685 1926 1930 O
clinical 686 694 1931 1939 O
and/or 695 701 1940 1946 O
radiographic 702 714 1947 1959 O
evidence 715 723 1960 1968 O
of 724 726 1969 1971 O
first 727 732 1972 1977 O
recurrence 733 743 1978 1988 O
of 744 746 1989 1991 O
glioblastoma 747 759 1992 2004 B-cancer
and 760 763 2005 2008 O
be 764 766 2009 2011 O
eligible 767 775 2012 2020 O
for 776 779 2021 2024 O
salvage 780 787 2025 2032 B-treatment
surgical 788 796 2033 2041 I-treatment
resection 797 806 2042 2051 I-treatment
as 807 809 2052 2054 O
deemed 810 816 2055 2061 O
by 817 819 2062 2064 O
the 820 823 2065 2068 O
site 824 828 2069 2073 O
Investigator 829 841 2074 2086 O
. 841 842 2086 2087 O
For 843 846 2088 2091 O
Arm 847 850 2092 2095 O
E 851 852 2096 2097 O
: 852 853 2097 2098 O
Patients 854 862 2099 2107 O
must 863 867 2108 2112 O
have 868 872 2113 2117 O
clinical 873 881 2118 2126 O
and/or 882 888 2127 2133 O
radiographic 889 901 2134 2146 O
evidence 902 910 2147 2155 O
of 911 913 2156 2158 O
recurrence 914 924 2159 2169 O
of 925 927 2170 2172 O
diffuse 928 935 2173 2180 B-cancer
midline 936 943 2181 2188 I-cancer
glioma 944 950 2189 2195 I-cancer
defined 951 958 2196 2203 O
as 959 961 2204 2206 O
a 962 963 2207 2208 O
WHO 964 967 2209 2212 O
Grade 968 973 2213 2218 B-cancer
IV 974 976 2219 2221 I-cancer
glioma 977 983 2222 2228 I-cancer
involving 984 993 2229 2238 O
the 994 997 2239 2242 O
pons 998 1002 2243 2247 O
, 1002 1003 2247 2248 O
thalamus 1004 1012 2249 2257 O
or 1013 1015 2258 2260 O
spinal 1016 1022 2261 2267 O
cord 1023 1027 2268 2272 O
, 1027 1028 2272 2273 O
and 1029 1032 2274 2277 O
be 1033 1035 2278 2280 O
eligible 1036 1044 2281 2289 O
for 1045 1048 2290 2293 O
salvage 1049 1056 2294 2301 O
surgical 1057 1065 2302 2310 O
resection 1066 1075 2311 2320 O
as 1076 1078 2321 2323 O
deemed 1079 1085 2324 2330 O
by 1086 1088 2331 2333 O
the 1089 1092 2334 2337 O
site 1093 1097 2338 2342 O
Investigator 1098 1110 2343 2355 O

For 0 3 2356 2359 O
Arms 4 8 2360 2364 O
A 9 10 2365 2366 O
, 10 11 2366 2367 O
B 12 13 2368 2369 O
, 13 14 2369 2370 O
C 15 16 2371 2372 O
, 16 17 2372 2373 O
prior 18 23 2374 2379 B-treatment
bevacizumab 24 35 2380 2391 I-treatment
for 36 39 2392 2395 O
treatment 40 49 2396 2405 B-treatment
( 50 51 2406 2407 O
allowable 51 60 2407 2416 O
for 61 64 2417 2420 O
Arms 65 69 2421 2425 O
D 70 71 2426 2427 O
, 71 72 2427 2428 O
E 73 74 2429 2430 O
, 74 75 2430 2431 O
and 76 79 2432 2435 O
F 80 81 2436 2437 O
) 81 82 2437 2438 O

From 0 4 2439 2443 O
the 5 8 2444 2447 O
projected 9 18 2448 2457 O
start 19 24 2458 2463 O
of 25 27 2464 2466 O
scheduled 28 37 2467 2476 O
study 38 43 2477 2482 B-treatment
treatment 44 53 2483 2492 I-treatment

Histologically 0 14 2493 2507 O
confirmed 15 24 2508 2517 O
World 25 30 2518 2523 O
Health 31 37 2524 2530 O
Organization 38 50 2531 2543 O
Grade 51 56 2544 2549 B-cancer
IV 57 59 2550 2552 I-cancer
glioblastoma 60 72 2553 2565 I-cancer
. 72 73 2565 2566 O
WHO 74 77 2567 2570 O
Grade 78 83 2571 2576 B-cancer
IV 84 86 2577 2579 I-cancer
gliomas 87 94 2580 2587 I-cancer
will 95 99 2588 2592 O
be 100 102 2593 2595 O
allowed 103 110 2596 2603 O
on 111 113 2604 2606 O
protocol 114 122 2607 2615 O
. 122 123 2615 2616 O
For 124 127 2617 2620 O
Arm 128 131 2621 2624 O
D 132 133 2625 2626 O
: 133 134 2626 2627 O
Must 135 139 2628 2632 O
have 140 144 2633 2637 O
a 145 146 2638 2639 O
WHO 147 150 2640 2643 O
Grade 151 156 2644 2649 O
IV 157 159 2650 2652 O
glioma 160 166 2653 2659 O
as 167 169 2660 2662 O
per 170 173 2663 2666 O
above 174 179 2667 2672 O
and 180 183 2673 2676 O
tumor 184 189 2677 2682 B-cancer
must 190 194 2683 2687 O
harbor 195 201 2688 2694 O
a 202 203 2695 2696 O
histone 204 211 2697 2704 O
H3 212 214 2705 2707 O
K27 215 218 2708 2711 O
M 218 219 2711 2712 O
mutation 220 228 2713 2721 O
as 229 231 2722 2724 O
evidenced 232 241 2725 2734 O
by 242 244 2735 2737 O
testing 245 252 2738 2745 O
any 253 256 2746 2749 O
tumor 257 262 2750 2755 O
sample 263 269 2756 2762 O
with 270 274 2763 2767 O
an 275 277 2768 2770 O
immunohistochemistry 278 298 2771 2791 B-treatment
or 299 301 2792 2794 O
DNA 302 305 2795 2798 B-treatment
sequencing 306 316 2799 2809 I-treatment
test 317 321 2810 2814 I-treatment
. 321 322 2814 2815 O
For 323 326 2816 2819 O
Arm 327 330 2820 2823 O
E 331 332 2824 2825 O
: 332 333 2825 2826 O
Must 334 338 2827 2831 O
have 339 343 2832 2836 O
clinical 344 352 2837 2845 O
and/or 353 359 2846 2852 O
radiographic 360 372 2853 2865 O
evidence 373 381 2866 2874 O
of 382 384 2875 2877 O
a 385 386 2878 2879 O
diffuse 387 394 2880 2887 B-cancer
midline 395 402 2888 2895 I-cancer
glioma 403 409 2896 2902 I-cancer
defined 410 417 2903 2910 O
as 418 420 2911 2913 O
a 421 422 2914 2915 O
WHO 423 426 2916 2919 O
Grade 427 432 2920 2925 O
IV 433 435 2926 2928 O
glioma 436 442 2929 2935 O
involving 443 452 2936 2945 O
the 453 456 2946 2949 O
brainstem 457 466 2950 2959 O
, 466 467 2959 2960 O
thalamus 468 476 2961 2969 O
or 477 479 2970 2972 O
spinal 480 486 2973 2979 O
cord 487 491 2980 2984 O
and 492 495 2985 2988 O
be 496 498 2989 2991 O
eligible 499 507 2992 3000 O
for 508 511 3001 3004 O
salvage 512 519 3005 3012 B-treatment
surgical 520 528 3013 3021 I-treatment
resection 529 538 3022 3031 I-treatment
as 539 541 3032 3034 O
deemed 542 548 3035 3041 O
by 549 551 3042 3044 O
the 552 555 3045 3048 O
site 556 560 3049 3053 O
Investigator 561 573 3054 3066 O
. 573 574 3066 3067 O
For 575 578 3068 3071 O
Arm 579 582 3072 3075 O
F 583 584 3076 3077 O
: 584 585 3077 3078 O
Must 586 590 3079 3083 O
have 591 595 3084 3088 O
a 596 597 3089 3090 O
diffuse 598 605 3091 3098 O
midline 606 613 3099 3106 O
glioma 614 620 3107 3113 O
, 620 621 3113 3114 O
defined 622 629 3115 3122 O
as 630 632 3123 3125 O
a 633 634 3126 3127 O
WHO 635 638 3128 3131 O
Grade 639 644 3132 3137 O
IV 645 647 3138 3140 O
glioma 648 654 3141 3147 O
involving 655 664 3148 3157 O
the 665 668 3158 3161 O
brainstem 669 678 3162 3171 O
, 678 679 3171 3172 O
thalamus 680 688 3173 3181 O
or 689 691 3182 3184 O
spinal 692 698 3185 3191 O
cord 699 703 3192 3196 O
, 703 704 3196 3197 O
without 705 712 3198 3205 O
the 713 716 3206 3209 O
H3 717 719 3210 3212 O
K27 720 723 3213 3216 O
M 723 724 3216 3217 O
mutation 725 733 3218 3226 O
or 734 736 3227 3229 O
with 737 741 3230 3234 O
unknown 742 749 3235 3242 O
H3 750 752 3243 3245 O
mutation 753 761 3246 3254 O
status 762 768 3255 3261 O

History 0 7 3262 3269 O
of 8 10 3270 3272 O
allergic 11 19 3273 3281 O
reactions 20 29 3282 3291 O
attributed 30 40 3292 3302 O
to 41 43 3303 3305 O
compounds 44 53 3306 3315 O
of 54 56 3316 3318 O
similar 57 64 3319 3326 O
chemical 65 73 3327 3335 O
or 74 76 3336 3338 O
biologic 77 85 3339 3347 O
composition 86 97 3348 3359 O
to 98 100 3360 3362 O
ONC201 101 107 3363 3369 B-treatment
or 108 110 3370 3372 O
its 111 114 3373 3376 O
excipients 115 125 3377 3387 O

Karnofsky 0 9 3388 3397 B-clinical_variable
Performance 10 21 3398 3409 I-clinical_variable
Status 22 28 3410 3416 I-clinical_variable
( 29 30 3417 3418 I-clinical_variable
KPS 30 33 3418 3421 I-clinical_variable
) 33 34 3421 3422 I-clinical_variable
≥ 35 36 3423 3424 O
60 37 39 3425 3427 B-lower_bound
% 39 40 3427 3428 I-lower_bound
( 41 42 3429 3430 O
see 42 45 3430 3433 O
Appendix 46 54 3434 3442 O
A 55 56 3443 3444 O
) 56 57 3444 3445 O

Known 0 5 3446 3451 O
additional 6 16 3452 3462 O
malignancy 17 27 3463 3473 B-cancer
that 28 32 3474 3478 O
is 33 35 3479 3481 O
progressing 36 47 3482 3493 O
or 48 50 3494 3496 O
requires 51 59 3497 3505 O
active 60 66 3506 3512 O
treatment 67 76 3513 3522 B-treatment
within 77 83 3523 3529 O
3 84 85 3530 3531 B-upper_bound
years 86 91 3532 3537 I-upper_bound
of 92 94 3538 3540 O
start 95 100 3541 3546 O
of 101 103 3547 3549 O
study 104 109 3550 3555 B-treatment
drug 110 114 3556 3560 I-treatment
. 114 115 3560 3561 O
Exceptions 116 126 3562 3572 O
include 127 134 3573 3580 O
basal 135 140 3581 3586 B-cancer
cell 141 145 3587 3591 I-cancer
carcinoma 146 155 3592 3601 I-cancer
of 156 158 3602 3604 I-cancer
the 159 162 3605 3608 I-cancer
skin 163 167 3609 3613 I-cancer
, 167 168 3613 3614 O
squamous 169 177 3615 3623 B-cancer
cell 178 182 3624 3628 I-cancer
carcinoma 183 192 3629 3638 I-cancer
of 193 195 3639 3641 I-cancer
the 196 199 3642 3645 I-cancer
skin 200 204 3646 3650 I-cancer
, 204 205 3650 3651 O
or 206 208 3652 3654 O
in 209 211 3655 3657 B-cancer
situ 212 216 3658 3662 I-cancer
cervical 217 225 3663 3671 I-cancer
cancer 226 232 3672 3678 I-cancer
that 233 237 3679 3683 O
has 238 241 3684 3687 O
undergone 242 251 3688 3697 O
potentially 252 263 3698 3709 O
curative 264 272 3710 3718 B-treatment
therapy 273 280 3719 3726 I-treatment

Known 0 5 3727 3732 O
history 6 13 3733 3740 O
of 14 16 3741 3743 O
cardiac 17 24 3744 3751 B-chronic_disease
arrhythmias 25 36 3752 3763 I-chronic_disease
including 37 46 3764 3773 O
atrial 47 53 3774 3780 B-chronic_disease
fibrillation 54 66 3781 3793 I-chronic_disease
, 66 67 3793 3794 O
tachyarrhythmias 68 84 3795 3811 B-chronic_disease
or 85 87 3812 3814 O
bradycardia 88 99 3815 3826 B-chronic_disease
. 99 100 3826 3827 O
Receiving 101 110 3828 3837 O
therapeutic 111 122 3838 3849 B-treatment
agents 123 129 3850 3856 I-treatment
known 130 135 3857 3862 O
to 136 138 3863 3865 O
prolong 139 146 3866 3873 O
QT 147 149 3874 3876 O
interval 150 158 3877 3885 O
will 159 163 3886 3890 O
be 164 166 3891 3893 O
excluded 167 175 3894 3902 O
. 175 176 3902 3903 O
History 177 184 3904 3911 O
of 185 187 3912 3914 O
CHF 188 191 3915 3918 B-chronic_disease

MI 0 2 3919 3921 B-chronic_disease
or 3 5 3922 3924 O
stroke 6 12 3925 3931 B-chronic_disease
in 13 15 3932 3934 O
the 16 19 3935 3938 O
last 20 24 3939 3943 B-upper_bound
3 25 26 3944 3945 I-upper_bound
months 27 33 3946 3952 I-upper_bound
will 34 38 3953 3957 O
be 39 41 3958 3960 O
excluded 42 50 3961 3969 O

Male 0 4 3970 3974 B-gender

Male 0 4 3975 3979 B-gender
subjects 5 13 3980 3988 I-gender
should 14 20 3989 3995 O
agree 21 26 3996 4001 B-contraception_consent
to 27 29 4002 4004 I-contraception_consent
use 30 33 4005 4008 I-contraception_consent
adequate 34 42 4009 4017 I-contraception_consent
method 43 49 4018 4024 I-contraception_consent
of 50 52 4025 4027 I-contraception_consent
contraception 53 66 4028 4041 I-contraception_consent
starting 67 75 4042 4050 O
with 76 80 4051 4055 O
the 81 84 4056 4059 O
first 85 90 4060 4065 O
dose 91 95 4066 4070 O
of 96 98 4071 4073 O
study 99 104 4074 4079 O
therapy 105 112 4080 4087 B-treatment
through 113 120 4088 4095 O
120 121 124 4096 4099 B-upper_bound
days 125 129 4100 4104 I-upper_bound
after 130 135 4105 4110 I-upper_bound
the 136 139 4111 4114 O
last 140 144 4115 4119 O
dose 145 149 4120 4124 O
of 150 152 4125 4127 O
therapy 153 160 4128 4135 O

Must 0 4 4136 4140 O
be 5 7 4141 4143 O
12 8 10 4144 4146 B-upper_bound
weeks 11 16 4147 4152 I-upper_bound
from 17 21 4153 4157 O
radiotherapy 22 34 4158 4170 B-treatment

Pregnant 0 8 4171 4179 B-pregnancy
women 9 14 4180 4185 B-gender
because 15 22 4186 4193 O
ONC201 23 29 4194 4200 B-treatment
is 30 32 4201 4203 O
novel 33 38 4204 4209 O
agent 39 44 4210 4215 O
with 45 49 4216 4220 O
unknown 50 57 4221 4228 O
potential 58 67 4229 4238 O
for 68 71 4239 4242 O
teratogenic 72 83 4243 4254 B-treatment
or 84 86 4255 4257 O
abortifacient 87 100 4258 4271 O
effects 101 108 4272 4279 O
. 108 109 4279 4280 O
Because 110 117 4281 4288 O
there 118 123 4289 4294 O
is 124 126 4295 4297 O
an 127 129 4298 4300 O
unknown 130 137 4301 4308 O
but 138 141 4309 4312 O
potential 142 151 4313 4322 O
risk 152 156 4323 4327 O
for 157 160 4328 4331 O
adverse 161 168 4332 4339 O
events 169 175 4340 4346 O
in 176 178 4347 4349 O
nursing 179 186 4350 4357 O
infants 187 194 4358 4365 O
secondary 195 204 4366 4375 O
to 205 207 4376 4378 O
treatment 208 217 4379 4388 B-treatment
of 218 220 4389 4391 O
the 221 224 4392 4395 O
mother 225 231 4396 4402 O
with 232 236 4403 4407 O
ONC201 237 243 4408 4414 O
, 243 244 4414 4415 O
breastfeeding 245 258 4416 4429 O
should 259 265 4430 4436 O
be 266 268 4437 4439 O
discontinued 269 281 4440 4452 O
if 282 284 4453 4455 O
the 285 288 4456 4459 O
mother 289 295 4460 4466 O
is 296 298 4467 4469 O
treated 299 306 4470 4477 O
with 307 311 4478 4482 O
ONC201 312 318 4483 4489 O

Previous 0 8 4490 4498 B-treatment
first 9 14 4499 4504 I-treatment
line 15 19 4505 4509 I-treatment
therapy 20 27 4510 4517 I-treatment
with 28 32 4518 4522 O
at 33 35 4523 4525 O
least 36 41 4526 4531 O
radiotherapy 42 54 4532 4544 B-treatment
and 55 58 4545 4548 O
temozolomide 59 71 4549 4561 B-treatment
. 71 72 4561 4562 O
For 73 76 4563 4566 O
Arms 77 81 4567 4571 O
D 82 83 4572 4573 O
, 83 84 4573 4574 O
E 85 86 4575 4576 O
, 86 87 4576 4577 O
and 88 91 4578 4581 O
F 92 93 4582 4583 O
, 93 94 4583 4584 O
previous 95 103 4585 4593 B-treatment
first 104 109 4594 4599 I-treatment
line 110 114 4600 4604 I-treatment
therapy 115 122 4605 4612 I-treatment
with 123 127 4613 4617 O
at 128 130 4618 4620 O
least 131 136 4621 4626 O
radiotherapy 137 149 4627 4639 O

Prior 0 5 4640 4645 B-treatment
stereotactic 6 18 4646 4658 I-treatment
radiotherapy 19 31 4659 4671 I-treatment
, 31 32 4671 4672 O
convection 33 43 4673 4683 B-treatment
enhanced 44 52 4684 4692 I-treatment
delivery 53 61 4693 4701 I-treatment
( 62 63 4702 4703 I-treatment
CED 63 66 4703 4706 I-treatment
) 66 67 4706 4707 I-treatment
or 68 70 4708 4710 O
brachytherapy 71 84 4711 4724 B-treatment
must 85 89 4725 4729 O
have 90 94 4730 4734 O
had 95 98 4735 4738 O
a 99 100 4739 4740 O
biopsy 101 107 4741 4747 B-treatment
to 108 110 4748 4750 O
confirm 111 118 4751 4758 O
radiographic 119 131 4759 4771 O
progression 132 143 4772 4783 O
is 144 146 4784 4786 O
consistent 147 157 4787 4797 O
with 158 162 4798 4802 O
progressive 163 174 4803 4814 O
tumor 175 180 4815 4820 B-cancer
and 181 184 4821 4824 O
not 185 188 4825 4828 O
treatment 189 198 4829 4838 O
- 198 199 4838 4839 O
related 199 206 4839 4846 O
necrosis 207 215 4847 4855 O
. 215 216 4855 4856 O
If 217 219 4857 4859 O
the 220 223 4860 4863 O
recurrent 224 233 4864 4873 O
lesion 234 240 4874 4880 O
is 241 243 4881 4883 O
outside 244 251 4884 4891 O
of 252 254 4892 4894 O
any 255 258 4895 4898 O
prior 259 264 4899 4904 B-treatment
high 265 269 4905 4909 I-treatment
- 269 270 4909 4910 I-treatment
dose 270 274 4910 4914 I-treatment
radiation 275 284 4915 4924 I-treatment
target 285 291 4925 4931 I-treatment
volume 292 298 4932 4938 I-treatment
or 299 301 4939 4941 O
distant 302 309 4942 4949 O
from 310 314 4950 4954 O
the 315 318 4955 4958 O
prior 319 324 4959 4964 B-treatment
CED 325 328 4965 4968 I-treatment
or 329 331 4969 4971 O
brachytherapy 332 345 4972 4985 O
site 346 350 4986 4990 O
, 350 351 4990 4991 O
subjects 352 360 4992 5000 O
will 361 365 5001 5005 O
be 366 368 5006 5008 O
considered 369 379 5009 5019 O
eligible 380 388 5020 5028 O

The 0 3 5029 5032 O
effects 4 11 5033 5040 O
of 12 14 5041 5043 O
ONC201 15 21 5044 5050 B-treatment
on 22 24 5051 5053 O
the 25 28 5054 5057 O
developing 29 39 5058 5068 O
human 40 45 5069 5074 O
fetus 46 51 5075 5080 O
are 52 55 5081 5084 O
unknown 56 63 5085 5092 O
. 63 64 5092 5093 O
For 65 68 5094 5097 O
this 69 73 5098 5102 O
reason 74 80 5103 5109 O
, 80 81 5109 5110 O
women 82 87 5111 5116 B-gender
of 88 90 5117 5119 O
childbearing 91 103 5120 5132 O
potential 104 113 5133 5142 O
and 114 117 5143 5146 O
men 118 121 5147 5150 O
must 122 126 5151 5155 O
agree 127 132 5156 5161 B-contraception_consent
to 133 135 5162 5164 I-contraception_consent
use 136 139 5165 5168 I-contraception_consent
adequate 140 148 5169 5177 I-contraception_consent
contraception 149 162 5178 5191 I-contraception_consent
( 163 164 5192 5193 O
hormonal 164 172 5193 5201 B-contraception_consent
or 173 175 5202 5204 I-contraception_consent
barrier 176 183 5205 5212 I-contraception_consent
method 184 190 5213 5219 I-contraception_consent
of 191 193 5220 5222 I-contraception_consent
birth 194 199 5223 5228 I-contraception_consent
control 200 207 5229 5236 I-contraception_consent
; 207 208 5236 5237 O
abstinence 209 219 5238 5248 B-contraception_consent
) 219 220 5248 5249 O
prior 221 226 5250 5255 O
to 227 229 5256 5258 O
study 230 235 5259 5264 O
entry 236 241 5265 5270 O
and 242 245 5271 5274 O
for 246 249 5275 5278 O
the 250 253 5279 5282 O
duration 254 262 5283 5291 O
of 263 265 5292 5294 O
study 266 271 5295 5300 O
participation 272 285 5301 5314 O
. 285 286 5314 5315 O
Should 287 293 5316 5322 O
a 294 295 5323 5324 O
woman 296 301 5325 5330 B-gender
become 302 308 5331 5337 O
pregnant 309 317 5338 5346 B-pregnancy
or 318 320 5347 5349 O
suspect 321 328 5350 5357 B-pregnancy
she 329 332 5358 5361 I-pregnancy
is 333 335 5362 5364 I-pregnancy
pregnant 336 344 5365 5373 I-pregnancy
while 345 350 5374 5379 O
she 351 354 5380 5383 O
or 355 357 5384 5386 O
her 358 361 5387 5390 O
partner 362 369 5391 5398 O
is 370 372 5399 5401 O
participating 373 386 5402 5415 O
in 387 389 5416 5418 O
this 390 394 5419 5423 O
study 395 400 5424 5429 O
, 400 401 5429 5430 O
she 402 405 5431 5434 O
should 406 412 5435 5441 O
inform 413 419 5442 5448 O
her 420 423 5449 5452 O
treating 424 432 5453 5461 O
physician 433 442 5462 5471 O
immediately 443 454 5472 5483 O

Tumors 0 6 5484 5490 B-cancer
with 7 11 5491 5495 O
isocitrate 12 22 5496 5506 O
dehydrogenase 23 36 5507 5520 O
1 37 38 5521 5522 O
( 39 40 5523 5524 O
IDH1 40 44 5524 5528 O
) 44 45 5528 5529 O
or 46 48 5530 5532 O
IDH2 49 53 5533 5537 O
mutations 54 63 5538 5547 O
as 64 66 5548 5550 O
determined 67 77 5551 5561 O
by 78 80 5562 5564 O
immunohistochemistry 81 101 5565 5585 B-treatment
for 102 105 5586 5589 O
the 106 109 5590 5593 O
IDH1 110 114 5594 5598 O
R132H 115 120 5599 5604 O
variant 121 128 5605 5612 O
or 129 131 5613 5615 O
by 132 134 5616 5618 O
direct 135 141 5619 5625 O
sequencing 142 152 5626 5636 O
. 152 153 5636 5637 O
IDH1/2 154 160 5638 5644 O
- 160 161 5644 5645 O
mutant 161 167 5645 5651 O
gliomas 168 175 5652 5659 B-cancer
have 176 180 5660 5664 O
a 181 182 5665 5666 O
markedly 183 191 5667 5675 O
longer 192 198 5676 5682 O
overall 199 206 5683 5690 O
survival 207 215 5691 5699 O
rate 216 220 5700 5704 O
compared 221 229 5705 5713 O
to 230 232 5714 5716 O
those 233 238 5717 5722 O
with 239 243 5723 5727 O
IDH1/2 244 250 5728 5734 O
- 250 251 5734 5735 O
wildtype 251 259 5735 5743 O
glioma 260 266 5744 5750 O
( 267 268 5751 5752 O
Parsons 268 275 5752 5759 O
et 276 278 5760 5762 O
al 279 281 5763 5765 O
. 281 282 5765 5766 O
, 282 283 5766 5767 O
2008 284 288 5768 5772 O
; 288 289 5772 5773 O
Yan 290 293 5774 5777 O
et 294 296 5778 5780 O
al 297 299 5781 5783 O
. 299 300 5783 5784 O
, 300 301 5784 5785 O
2009 302 306 5786 5790 O
) 306 307 5790 5791 O
, 307 308 5791 5792 O
indicating 309 319 5793 5803 O
IDH1/2 320 326 5804 5810 O
- 326 327 5810 5811 O
mutant 327 333 5811 5817 O
gliomas 334 341 5818 5825 O
have 342 346 5826 5830 O
a 347 348 5831 5832 O
distinct 349 357 5833 5841 O
natural 358 365 5842 5849 O
history 366 373 5850 5857 O

Uncontrolled 0 12 5858 5870 O
intercurrent 13 25 5871 5883 O
illness 26 33 5884 5891 O
including 34 43 5892 5901 O
, 43 44 5901 5902 O
but 45 48 5903 5906 O
not 49 52 5907 5910 O
limited 53 60 5911 5918 O
to 61 63 5919 5921 O
, 63 64 5921 5922 O
ongoing 65 72 5923 5930 O
or 73 75 5931 5933 O
active 76 82 5934 5940 B-chronic_disease
infection 83 92 5941 5950 I-chronic_disease
or 93 95 5951 5953 O
psychiatric 96 107 5954 5965 B-chronic_disease
illness 108 115 5966 5973 I-chronic_disease
/ 115 116 5973 5974 I-chronic_disease
social 116 122 5974 5980 I-chronic_disease
situations 123 133 5981 5991 I-chronic_disease
that 134 138 5992 5996 O
would 139 144 5997 6002 O
limit 145 150 6003 6008 O
compliance 151 161 6009 6019 O
with 162 166 6020 6024 O
study 167 172 6025 6030 O
requirements 173 185 6031 6043 O

Unequivocal 0 11 6044 6055 O
evidence 12 20 6056 6064 O
of 21 23 6065 6067 O
progressive 24 35 6068 6079 O
disease 36 43 6080 6087 O
on 44 46 6088 6090 O
contrast 47 55 6091 6099 O
- 55 56 6099 6100 O
enhanced 56 64 6100 6108 O
brain 65 70 6109 6114 O
computerized 71 83 6115 6127 B-treatment
tomography 84 94 6128 6138 I-treatment
( 95 96 6139 6140 I-treatment
CT 96 98 6140 6142 I-treatment
) 98 99 6142 6143 I-treatment
or 100 102 6144 6146 O
magnetic 103 111 6147 6155 B-treatment
resonance 112 121 6156 6165 I-treatment
imaging 122 129 6166 6173 I-treatment
( 130 131 6174 6175 I-treatment
MRI 131 134 6175 6178 I-treatment
) 134 135 6178 6179 I-treatment
as 136 138 6180 6182 O
defined 139 146 6183 6190 O
by 147 149 6191 6193 O
Response 150 158 6194 6202 O
Assessment 159 169 6203 6213 O
in 170 172 6214 6216 O
Neuro 173 178 6217 6222 O
- 178 179 6222 6223 O
Oncology 179 187 6223 6231 O
Criteria 188 196 6232 6240 O
( 197 198 6241 6242 O
RANO 198 202 6242 6246 O
) 202 203 6246 6247 O
, 203 204 6247 6248 O
or 205 207 6249 6251 O
have 208 212 6252 6256 O
documented 213 223 6257 6267 O
recurrent 224 233 6268 6277 O
glioblastoma 234 246 6278 6290 B-cancer
on 247 249 6291 6293 O
diagnostic 250 260 6294 6304 O
biopsy 261 267 6305 6311 B-treatment

absolute 0 8 6312 6320 B-clinical_variable
neutrophil 9 19 6321 6331 I-clinical_variable
count 20 25 6332 6337 I-clinical_variable
≥ 26 27 6338 6339 O
1,500 28 33 6340 6345 B-lower_bound
/ 33 34 6345 6346 I-lower_bound
mcL 34 37 6346 6349 I-lower_bound

age 0 3 6350 6353 B-age
≥16 4 7 6354 6357 O
years 8 13 6358 6363 I-lower_bound

half 0 4 6364 6368 O
- 4 5 6368 6369 O
lives 5 10 6369 6374 O
from 11 15 6375 6379 O
any 16 19 6380 6383 O
investigational 20 35 6384 6399 B-treatment
agent 36 41 6400 6405 I-treatment

hemoglobin 0 10 6406 6416 B-clinical_variable
> 11 12 6417 6418 O
8.0 13 16 6419 6422 B-lower_bound
mg 17 19 6423 6425 I-lower_bound
/ 19 20 6425 6426 I-lower_bound
dL 20 22 6426 6428 I-lower_bound

leukocytes 0 10 6429 6439 B-clinical_variable
≥ 11 12 6440 6441 O
3,000 13 18 6442 6447 B-lower_bound
/ 18 19 6447 6448 I-lower_bound
mcL 19 22 6448 6451 I-lower_bound

platelets 0 9 6452 6461 B-clinical_variable
≥ 10 11 6462 6463 O
100,000 12 19 6464 6471 B-lower_bound
/ 19 20 6471 6472 I-lower_bound
mcL 20 23 6472 6475 I-lower_bound

total 0 5 6476 6481 B-clinical_variable
bilirubin 6 15 6482 6491 I-clinical_variable
< 16 17 6492 6493 O
2.0 18 21 6494 6497 B-upper_bound
x 22 23 6498 6499 I-upper_bound
upper 24 29 6500 6505 I-upper_bound
limit 30 35 6506 6511 I-upper_bound
of 36 38 6512 6514 I-upper_bound
normal 39 45 6515 6521 I-upper_bound

weeks 0 5 6522 6527 O
from 6 10 6528 6532 O
cytotoxic 11 20 6533 6542 B-treatment
therapy 21 28 6543 6550 I-treatment
( 29 30 6551 6552 O
except 30 36 6552 6558 O
23 37 39 6559 6561 O
days 40 44 6562 6566 O
for 45 48 6567 6570 O
temozolomide 49 61 6571 6583 B-treatment
and 62 65 6584 6587 O
6 66 67 6588 6589 O
weeks 68 73 6590 6595 O
from 74 78 6596 6600 O
nitrosoureas 79 91 6601 6613 B-treatment
) 91 92 6613 6614 O
, 92 93 6614 6615 O
6 94 95 6616 6617 O
weeks 96 101 6618 6623 O
from 102 106 6624 6628 O
antibodies 107 117 6629 6639 B-treatment
, 117 118 6639 6640 O
or 119 121 6641 6643 O
4 122 123 6644 6645 O
weeks 124 129 6646 6651 O
( 130 131 6652 6653 O
or 131 133 6653 6655 O
5 134 135 6656 6657 O
half 136 140 6658 6662 O
- 140 141 6662 6663 O
lives 141 146 6663 6668 O
, 146 147 6668 6669 O
whichever 148 157 6670 6679 O
is 158 160 6680 6682 O
shorter 161 168 6683 6690 O
) 168 169 6690 6691 O
from 170 174 6692 6696 O
other 175 180 6697 6702 O
anti 181 185 6703 6707 B-treatment
- 185 186 6707 6708 I-treatment
tumor 186 191 6708 6713 I-treatment
therapies 192 201 6714 6723 I-treatment

